Editing for non-native English speakers

Example 1:

Before

Angiogenesis inhibitors should be delay in patients with recent arterial thrombosis. Patient suffering from any major arterial thromboembolic event during angiogenesis inhibitor should stop their treatment immediately. No standard rule to decide if the drug can be reintroduce the drug safely after recovery and adequate thrombotic prevention is available.

Inhibition of angiogenesis and lymphangiogenesis by anti-VEGF could contribute to impair wound healing, particularly in the postoperative situation and therefore cause significant postoperative complications such as perforation, anastomosis leakages, fistulae, infections,… Because of these concerns, a period of at least 28 days is recommended between administration of angiogenesis inhibitors and any elective surgical procedure [73].

After

Angiogenesis inhibitors should be delayed in patients with recent arterial thrombosis. Patients suffering from any major arterial thromboembolic event during treatment with an angiogenesis inhibitor should stop their treatment immediately. At the current time, there is no standard rule regarding the reintroduction of these drugs upon recovery and following adequate thrombotic prevention.

The inhibition of angiogenesis and lymphangiogenesis by anti-VEGF drugs may impair wound healing. In the post-operative setting in particular, there is an increased risk of perforation, anastomosis leakage, fistulae, and infection. A wash-out period of 28 days is therefore recommended following the administration of angiogenesis inhibitors and prior to any elective surgical procedure [73].

Example 2:

Before

Fatigue is a common symptom induced by sunitinib (grade 1-2= 29%, grade 3=5%, 4=0%) but in this context, it is important to exclude hypothyroidism induced by anti VEGF. Sunitinib is the principal kinase inhibitor links with hypothyroidism but cautious is warranted with the other compounds until better characterisation.The mechanisms of hypothyroidism are unclear but sunitinib has been shown, in vitro, to have an antiperoxidase activity with impaired iodine uptake [77]. All patients treated with sunitinib, should be regularly monitored for TSH and treated if necessary. In case of hypothyroidism, anti-VEGF treatment should not be discontinued.

After

Fatigue is a common symptom induced by sunitinib (grade 1 – 2, 29%; grade 3, 5%; grade 4, 0%) but as hypothyroidism can be induced by anti-VEGF treatment, it is important to exclude hypothyroidism as the root cause. Kinase inhibitors, principally sunitinib, have been linked to hypothyroidism and caution regarding this adverse event is warranted until the safety of these molecules can be fully determined. The mechanisms of hypothyroidism are unclear but sunitinib has been shown, in vitro, to have antiperoxidase activity with impaired iodine uptake [77]. All patients treated with sunitinib should have their TSH levels regularly monitored and treatment for hypothyroidism should be provided if necessary. Anti-VEGF treatment should not be discontinued in the event of hypothyroidism.

Exemple 3:

Before

A success was defined as either CR, PR or SD at 6-8 weeks. The Simon one sample two stage testing procedure was used with the following hypotheses: P_o=0.10, P₁=.25, α=0.15 and β= 0.10.¹⁷ According to those hypotheses, the total sample size for this trial was 37 patients; the trial could be discontinued earlier if <1 success was observed after 17 patients. At least 6 out of 37 patients should achieve a SD or a PR at 6-8 weeks to consider that the study met its primary end point.

After

Success was defined as either a CR, PR or SD at 6-8 weeks. The Simon optimal one-sample two-stage testing procedure was used with the following hypotheses: P_o=0.10, P₁=.25, α=0.15 and β= 0.10.¹⁷ According to these hypotheses, 37 patients needed to be recruited to the trial. At least 6 out of 37 patients were required to achieve SD or PR at 6-8 weeks post-treatment for the study to meet its primary end point. The trial was to be discontinued if <1 success was observed after 17 patients had been treated.

_____________________________

Translation from English to French

Before

The number of injections may be important for patients who struggle with flu-like symptoms occurring after injections.
Reducing the number of days with flu-like symptoms by reducing the number of injections may increase compliance to HCV therapy.
The number of injections may be important for patients who struggle with flu-like symptoms occurring after injections.
Reducing the number of days with flu-like symptoms by reducing the number of injections may increase compliance to HCV therapy. The burden of HCV treatment is a major hurdle to achieving cure.
The less complex a treatment regimen, the better the adherence to therapy.
Many patients are concerned about the side effects of HCV therapy prior to treatment and may be reluctant to initiate treatment.

After

Pour les patients, le nombre d’injections peut se révéler important quand ils luttent contre les symptômes grippaux qui apparaissent après les injections.
En réduisant le nombre de jours pendant lesquels les patients souffrent de symptômes grippaux, et en diminuant le nombre d’injections, la compliance du patient au traitement contre l’hépatite C peut s’améliorer.
La lourdeur du traitement contre l’hépatite C est un obstacle majeur pour que le patient respecte son traitement.
Plus le schéma thérapeutique est simple, plus le patient adhérera au traitement.
De nombreux patients se sentent concernés par les effets secondaires du traitement anti-hépatite C même avant de commencer une thérapie ce qui peut les rendre réticents au traitement.